LEXINGTON, Mass., Oct. 18 /PRNewswire/ -- Hypnion, Inc. (http://www.hypnion.com/), an innovative neuroscience drug discovery company focused on sleep-wake neurobiology and drug development, announced today that the company has relocated its corporate headquarters from Worcester, MA to Lexington, MA. The Company has leased 33,647 square feet in the newly renovated Lexington Technology Park, previously the corporate headquarters of Raytheon Company.
"We are delighted to move into this state-of-the-art building," said John F. Dee, President and CEO of Hypnion. "The new facility will support our core research and development activities as our programs progress into the next phase of clinical development. Lexington Technology Park provided us with an ideal location, and the opportunity to design a space that specifically fit our needs."
Hypnion, Inc. is the second tenant to move into the newly renovated 95- acre property, developed by Patriot Partners of Framingham, MA. "We're excited to welcome Hypnion to their new corporate home in Lexington Technology Park. Together we have developed a unique and modern facility, which will allow for Hypnion's continued growth," said Stephen Rice, Principal of Patriot Partners.
Hypnion, Inc.'s new address is 500 Patriot Way, Lexington, MA, 02421, telephone 781 778-0300, facsimile 781 778-0303.
About Hypnion -- Hypnion is a neuroscience drug discovery company whose objective is to become the worldwide leader in sleep-wake neurobiology and pharmaceutical development. The company was founded by prominent and highly regarded scientists in the field of sleep disorder research to enable the discovery and development of novel therapies.
The company is addressing a tremendous worldwide market opportunity to serve people suffering from the broad category of sleep disorders, which includes disorders of sleep (e.g., insomnia, sleep apnea, restless leg syndrome), disorders of wakefulness and attention (illnesses causing excessive sleepiness or chronic fatigue, ADHD) and circadian rhythm abnormalities. Recent research indicates that sleep disorders not only depress the immune system but may also make us vulnerable to many other diseases including diabetes, high blood pressure, obesity, heart failure, and even stroke or depression. Current therapies for these conditions have significant limitations, especially when used chronically or for treating the elderly.
Hypnion has proprietary rights to the worlds' most advanced pre-clinical sleep-wake system, SCORE-2000(TM), which is highly predictive of human response for many sleep-wake efficacy and side-effect variables, significantly lowering clinical trial risk. The system allows high-throughput testing of drug candidates at the pre-clinical stage to optimize the next generation of safe, non-addictive therapies for this vast and untreated market.
Michael E. Fitzgerald
VP, Finance & Administration, & CFO